NextCell Pharma AB (NXTCL.ST)
SEK 2.42
(-13.57%)
SEK 2.42
(-13.57%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | -1.03 SEK | 11.21% |
| 2023 | -1.16 SEK | -14.85% |
| 2022 | -1.01 SEK | -22.22% |
| 2021 | -0.81 SEK | -1.25% |
| 2020 | -0.89 SEK | 41.61% |
| 2019 | -1.45 SEK | 0.72% |
| 2018 | -1.65 SEK | -6.15% |
| 2017 | -3.34 SEK | 32.99% |
| 2016 | -4.37 SEK | -11.49% |
| 2015 | -4.14 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q4 | -0.22 SEK | 15.38% |
| 2024 Q1 | -0.28 SEK | -12.0% |
| 2024 Q2 | -0.29 SEK | -3.57% |
| 2024 Q3 | -0.26 SEK | 10.34% |
| 2023 Q3 | -0.32 SEK | 3.03% |
| 2023 Q1 | -0.26 SEK | -4.0% |
| 2023 FY | - SEK | -17.17% |
| 2023 Q4 | -0.25 SEK | 21.88% |
| 2023 Q2 | -0.33 SEK | -26.92% |
| 2022 Q3 | -0.27 SEK | 6.9% |
| 2022 Q1 | -0.19 SEK | -46.15% |
| 2022 Q2 | -0.29 SEK | -52.63% |
| 2022 Q4 | -0.24 SEK | 11.11% |
| 2022 FY | - SEK | -22.22% |
| 2021 Q3 | -0.19 SEK | 29.63% |
| 2021 FY | - SEK | -1.25% |
| 2021 Q1 | -0.23 SEK | -4.55% |
| 2021 Q2 | -0.27 SEK | -17.39% |
| 2021 Q4 | -0.13 SEK | 31.58% |
| 2020 Q4 | -0.22 SEK | 12.0% |
| 2020 Q3 | -0.25 SEK | -13.64% |
| 2020 Q2 | -0.22 SEK | -22.22% |
| 2020 Q1 | -0.18 SEK | 69.49% |
| 2020 FY | - SEK | 41.61% |
| 2019 Q1 | -0.43 SEK | -26.47% |
| 2019 FY | - SEK | 0.72% |
| 2019 Q3 | -0.34 SEK | -30.77% |
| 2019 Q4 | -0.59 SEK | -73.53% |
| 2019 Q2 | -0.26 SEK | 39.53% |
| 2018 Q4 | -0.34 SEK | -9.68% |
| 2018 FY | - SEK | -6.15% |
| 2018 Q1 | -0.32 SEK | 31.91% |
| 2018 Q2 | -0.42 SEK | -31.25% |
| 2018 Q3 | -0.31 SEK | 26.19% |
| 2017 Q4 | -0.47 SEK | 29.85% |
| 2017 Q1 | -0.46 SEK | -4.55% |
| 2017 Q2 | -0.06 SEK | 87.65% |
| 2017 Q3 | -0.67 SEK | -1079.58% |
| 2017 FY | - SEK | 32.99% |
| 2016 Q1 | -0.52 SEK | 0.0% |
| 2016 FY | - SEK | -11.49% |
| 2016 Q4 | -0.44 SEK | 22.81% |
| 2016 Q3 | -0.57 SEK | -6.94% |
| 2016 Q2 | -0.53 SEK | -2.3% |
| 2015 FY | - SEK | 0.0% |